Targeted Inhibition of the FACT (Facilitates Chromatin Transcription) Complex as a Novel Therapeutic Approach in Aggressive Childhood Cancers

靶向抑制 FACT（促进染色质转录）复合物作为侵袭性儿童癌症的新型治疗方法

• 批准号: nhmrc : 1085411
• 负责人: A/Pr David Ziegler
• 金额: $ 68.65万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeted-inhibition-fact-childhood-cancers/519085
• 关键词: Targeted; Inhibition; FACT; Facilitates; Chromatin

Our research focusses on the most aggressive of all childhood cancers, and our aim is to develop novel therapies for these malignancies. We have discovered a new drug target called "FACT" in aggressive brain and solid tumours of childhood. Targeting FACT with a new class of drugs termed "curaxins" has a powerful anti-tumour effect. We aim to investigate the potential of these drugs as a new, effective therapy for incurable childhood cancers.

我们的研究重点是所有儿童癌症中最具侵袭性的癌症，我们的目标是为这些恶性肿瘤开发新的疗法。我们在儿童侵袭性脑肿瘤和实体瘤中发现了一种名为“FACT”的新药靶点。用一种名为“curaxins”的新型药物靶向FACT具有强大的抗肿瘤作用。我们的目标是研究这些药物作为一种新的，有效的治疗不可治愈的儿童癌症的潜力。